A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus Type 1 infection in a human-SCID chimera model of thermal injury.

Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 x 10(3) PFU/kg of HSV-1 (0% survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92% survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5% of them survived, respectively. However, 75% of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.

[1]  G. Pizzolo,et al.  Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. , 2001, Trends in immunology.

[2]  K. Schulze-Osthoff,et al.  Enhancement of T Cell Receptor Signaling by a Mild Oxidative Shift in the Intracellular Thiol Pool1 , 2000, The Journal of Immunology.

[3]  D. Herndon,et al.  Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. , 1999, Journal of immunology.

[4]  D. Herndon,et al.  Burn‐associated Candida albicans infection caused by CD30+ type 2 T cells , 1998, Journal of leukocyte biology.

[5]  H. Okamura,et al.  Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. , 1998, Journal of immunology.

[6]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[7]  D. Carvajal,et al.  IL‐12‐Deficient Mice Are Defective but Not Devoid of Type 1 Cytokine Responses , 1996, Annals of the New York Academy of Sciences.

[8]  M. de Carli,et al.  Markers of Th1 and Th2 cells. , 1996, Chemical immunology.

[9]  A. Enk,et al.  Interleukin‐12 is produced by dendritic cells and mediates T helper 1 development as well as interferon‐γ production by T helper 1 cells , 1996, European journal of immunology.

[10]  W. Dietrich,et al.  Genetic Susceptibility to Leishmania: IL-12 Responsiveness in TH1 Cell Development , 1996, Science.

[11]  P. Lehmann,et al.  The human immune system in hu-PBL-SCID mice. , 1995, Immunology today.

[12]  J. Meakins,et al.  Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. , 1995 .

[13]  Makiko Kobayashi,et al.  CD4+ contrasuppressor T cells improve the resistance of thermally injured mice infected with HSV , 1995, Journal of leukocyte biology.

[14]  S. Szabo,et al.  Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. , 1995, Immunity.

[15]  G. Trinchieri,et al.  Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. , 1995, Journal of immunology.

[16]  Y. Barlow.  T lymphocytes and immunosuppression in the burned patient: a review. , 1994, Burns : journal of the International Society for Burn Injuries.

[17]  P. Puccetti,et al.  Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. , 1994, The Journal of infectious diseases.

[18]  C. Natanson,et al.  Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis , 1994, Annals of Internal Medicine.

[19]  A. Heiligenhaus,et al.  Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells. , 1993, Journal of immunology.

[20]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[21]  C. Maliszewski,et al.  The interleukin-4 receptor: structure, function, and signal transduction. , 1992, Chemical immunology.

[22]  J. Berzofsky,et al.  Role of T‐Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection , 1992, Immunological reviews.

[23]  J. Farrant,et al.  Phenotypic and Functional Studies of Human Peripheral Blood Lymphocytes Engrafted in scid Mice , 1991, Immunological reviews.

[24]  B. Rouse,et al.  The mouse model and understanding immunity to herpes simplex virus. , 1991, Reviews of infectious diseases.

[25]  S. Kaufmann,et al.  The role of T-cell subsets and cytokines in the regulation of infection. , 1991, Immunology today.

[26]  R. Fernandez-Botran,et al.  Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins , 1991, The Journal of experimental medicine.

[27]  D. Lynch,et al.  Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. , 1991, Blood.

[28]  A. Weinberg,et al.  IL-4 directs the development of Th2-like helper effectors. , 1990, Journal of immunology.

[29]  W. Paul,et al.  Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4- producing cells , 1990, The Journal of experimental medicine.

[30]  R. Pollard,et al.  Patterns of interferon-γ production by peripheral blood mononuclear cells from patients with human immunodeficiency virus infection , 1990 .

[31]  F. Odds,et al.  Characterization of Candida isolates from pediatric burn patients , 1988, Journal of clinical microbiology.

[32]  E. Caplan,et al.  The septic multiple-trauma patient. , 1988, Critical care clinics.

[33]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[34]  O. Jonasson,et al.  Herpes simplex virus and cytomegalovirus infections in burned patients. , 1986, The Journal of trauma.

[35]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[36]  R. Königová,et al.  Fatal outcome of cytomegalovirus infections in severe burns. , 1980, Acta chirurgiae plasticae.

[37]  R. Konigová,et al.  Cytomegalovirus infection in severely burned patients. , 1978, Acta chirurgiae plasticae.

[38]  A. Notkins.  Viral Infections: Mechanisms of Immunologic Defense and Injury , 1974 .

[39]  G. Trinchieri,et al.  Immunomodulatory functions and molecular regulation of IL-12. , 1997, Chemical immunology.

[40]  S. Romagnani,et al.  The role of TH1 and TH2 subsets in human infectious diseases. , 1994, Trends in microbiology.

[41]  W. Paul,et al.  Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, Annual review of immunology.

[42]  D. Lancki,et al.  Differential regulation of murine T lymphocyte subsets. , 1993, Annual review of immunology.

[43]  S. Opal,et al.  The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. , 1993, The Journal of infectious diseases.

[44]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.